Stock Screener App

무료 - Play StoreApp Store

설치하다 설치하다

Dow:

Nasdaq:

S&P 500:

GMAB

$57.061.01%0.57

시간 외 거래: 57.07+0.01 +0.02%

Genmab Adr (GMAB)

Date: O: H: L: C: Vol:

Genmab Adr 주식(GMAB)의 최신 뉴스

Genmab A/S Stock 12‑Month Price Target Raised to $61.56, Implies 7% Upside - TradingView

Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer - The Manila Times

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy - Zacks Investment Research

Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - The Manila Times

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer - The Manila Times

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer - GlobeNewswire Inc.

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer - The Manila Times

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer - GlobeNewswire Inc.

Genmab A/S Estimates – OMXCOP:GMAB - TradingView

Genmab (GMAB) Shares Edge Higher as Price Ticks Up 1.48% to $39.07 - Put Dominated - https://www.siam.in/

Genmab reports USD 4.24 billion DARZALEX sales and BofA targets Genmab stock at DKK 2,850 - ad-hoc-news.de

Genmab A/S (GMAB.CO) Stock Price, News, Quote & History - Yahoo! Finance Canada

HC Wainwright raises target for Genmab stock from USD 40 to USD 50 - ad-hoc-news.de

Genmab A/S (GMAB) Stock Price, News, Quote & History - Yahoo! Finance Canada

Genmab A/S ADS (GMAB) Ticks Up 0.81% as Shares Hold Above $37 - Exhaustion Gap - www.dars.gov.et

Genmab A/S ADS (GMAB) Ticks Up 0.81% as Shares Hold Above $37 - Last Point Resistance - https://www.siam.in/

Genmab stock gains as capital increase and updated Articles of Association support growth plans - AD HOC NEWS

Genmab A/S ADS (GMAB) Slips 1.64% as Shares Test Key Support Zone - Mutual Fund Flow - https://www.siam.in/

Genmab A/S ADS (GMAB) Slips 1.64% as Shares Test Key Support Zone - Block Trade Flow - https://www.dars.gov.et/

Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members - The Manila Times

Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members - Yahoo Finance

Genmab A/S Stock 12‑Month Price Target Raised to $42, Implies 9% Upside - TradingView

AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL - Zacks Investment Research

Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? - Zacks Investment Research

Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge - The Motley Fool

Genmab stock gains 5.32 percent on Rina-S data - AD HOC NEWS

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma - GlobeNewswire Inc.

Genmab stock after-hours at EUR 319.90: minus 0.03 percent versus the prior close at Lang & Schwarz - AD HOC NEWS

Genmab reports Rina-S results. Genmab stock falls 1.95 percent - AD HOC NEWS

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer - GlobeNewswire Inc.

Major Shareholder Announcement - GlobeNewswire Inc.

Genmab A/S Stock 12‑Month Price Target Raised to $39.56, Implies 14% Upside - TradingView

HC Wainwright keeps Buy on Genmab stock at USD 40 target - AD HOC NEWS

GMAB Q2 2026 Earnings: EPS Beats Consensus by 36.6% as Shares Edge Higher - Earnings Surprise Report - https://www.dars.gov.et/

Genmab stock last trades at DKK 2,282.00 on September 28, 2026 - AD HOC NEWS

Genmab stock at DKK 2,277 on September 25, 2026, up 0.40 percent - AD HOC NEWS

Genmab stock gains 0.8 percent ahead of the open - AD HOC NEWS

Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewswire Inc.

Genmab stock heads into the open after a 0.84 percent gain - AD HOC NEWS

Genmab stock gains as Kempen raises target to DKK 3,300 - AD HOC NEWS

Genmab stock heads into the open after a 10.80 percent year gain - AD HOC NEWS

Genmab stock advances as Q4 readouts stay on track - AD HOC NEWS

GMAB Q2 2026 Earnings: EPS Beats Consensus by 36.6% as Shares Edge Higher - Earnings Analysis - www.dars.gov.et

GMAB Q2 2026 Earnings: EPS Beats Consensus by 36.6% as Shares Edge Higher - Earnings Cycle Outlook - dars.gov.et

Genmab stock holds steady after first-half 2026 earnings update - AD HOC NEWS

Genmab stock gains as petosemtamab and Q2 figures draw focus - AD HOC NEWS

Genmab stock gains as petosemtamab Phase 3 start and strong Q2 figures support valuation - AD HOC NEWS

Genmab stock heads into the open after a modest gain - AD HOC NEWS

Genmab stock gains as HC Wainwright lifts Q3 earnings estimates and Phase 3 petosemtamab trial begin - AD HOC NEWS

Genmab stock gains as HC Wainwright lifts earnings estimates and confirms Buy rating - AD HOC NEWS

GMAB와(과) 유사한 종목

RPRX$67.181.90%

RVMD$191.310.55%

ONC$370.330.33%

ROIV$36.911.63%

INSM$112.580.89%

INCY$120.393.07%